{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:02:46Z","timestamp":1790089366648,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170975"],"award-info":[{"award-number":["32170975"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171437"],"award-info":[{"award-number":["32171437"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00018-024-05390-1","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:03:13Z","timestamp":1723554193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lys-63-specific deubiquitinase BRCC36 enhances the sensitivity of multiple myeloma cells to lenalidomide by inhibiting lysosomal degradation of cereblon"],"prefix":"10.1007","volume":"81","author":[{"given":"Busong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-1520","authenticated-orcid":false,"given":"Liang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"6","key":"5390_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D (2016) Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol 43(6):676\u2013681","journal-title":"Semin Oncol"},{"issue":"1","key":"5390_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-018-3546-8","volume":"98","author":"H Goldschmidt","year":"2019","unstructured":"Goldschmidt H, Ashcroft J, Szabo Z, Garderet L (2019) Navigating the treatment landscape in multiple myeloma: which combinations to use and when? Ann Hematol 98(1):1\u201318","journal-title":"Ann Hematol"},{"key":"5390_CR3","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","volume":"9","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Usmani SZ (2018) CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol 9:2134","journal-title":"Front Immunol"},{"issue":"S1","key":"5390_CR4","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.5045\/br.2020.S008","volume":"55","author":"JH Lee","year":"2020","unstructured":"Lee JH, Kim SH (2020) Treatment of relapsed and refractory multiple myeloma. Blood Res 55(S1):S43\u2013S53","journal-title":"Blood Res"},{"issue":"1","key":"5390_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00344-2","volume":"10","author":"JA Hernandez-Rivas","year":"2022","unstructured":"Hernandez-Rivas JA, Rios-Tamayo R, Encinas C, Alonso R, Lahuerta JJ (2022) The changing landscape of relapsed and\/or refractory multiple myeloma (MM): fundamentals and controversies. Biomark Res 10(1):1","journal-title":"Biomark Res"},{"issue":"7111","key":"5390_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/nature05175","volume":"443","author":"S Angers","year":"2006","unstructured":"Angers S, Li T, Yi X, MacCoss MJ, Moon RT, Zheng N (2006) Molecular architecture and assembly of the DDB1\u2013CUL4A ubiquitin ligase machinery. Nature 443(7111):590\u2013593","journal-title":"Nature"},{"issue":"5971","key":"5390_CR7","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327(5971):1345\u20131350","journal-title":"Science"},{"issue":"6168","key":"5390_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1126\/science.1244917","volume":"343","author":"G Lu","year":"2014","unstructured":"Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS et al (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343(6168):305\u2013309","journal-title":"Science"},{"issue":"6168","key":"5390_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1126\/science.1244851","volume":"343","author":"J Kronke","year":"2014","unstructured":"Kronke J, Udeshi ND, Narla A, Grauman P, Hurst SN, McConkey M et al (2014) Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343(6168):301\u2013305","journal-title":"Science"},{"issue":"11","key":"5390_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.tibs.2009.07.002","volume":"34","author":"S Jackson","year":"2009","unstructured":"Jackson S, Xiong Y (2009) CRL4s: the CUL4-RING E3 ubiquitin ligases. Trends Biochem Sci 34(11):562\u2013570","journal-title":"Trends Biochem Sci"},{"issue":"1\u20134","key":"5390_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.bbrc.2018.11.058","volume":"507","author":"J Tao","year":"2018","unstructured":"Tao J, Yang J, Xu G (2018) The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners. Biochem Biophys Res Commun 507(1\u20134):443\u2013449","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"5390_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jiang X, Feng F, Liu W, Sun H (2020) Degradation of proteins by PROTACs and other strategies. Acta Pharm Sin B 10(2):207\u2013238","journal-title":"Acta Pharm Sin B"},{"issue":"6241","key":"5390_CR13","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1126\/science.aab1433","volume":"348","author":"GE Winter","year":"2015","unstructured":"Winter GE, Buckley DL, Paulk J, Roberts JM, Souza A, Dhe-Paganon S et al (2015) Drug Development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241):1376\u20131381","journal-title":"Science"},{"issue":"6","key":"5390_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.chembiol.2015.05.009","volume":"22","author":"J Lu","year":"2015","unstructured":"Lu J, Qian Y, Altieri M, Dong H, Wang J, Raina K et al (2015) Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem Biol 22(6):755\u2013763","journal-title":"Chem Biol"},{"issue":"41","key":"5390_CR15","doi-asserted-by":"publisher","first-page":"29573","DOI":"10.1074\/jbc.M113.472092","volume":"288","author":"G Xu","year":"2013","unstructured":"Xu G, Jiang X, Jaffrey SR (2013) A mental retardation-linked nonsense mutation in cereblon is rescued by proteasome inhibition. J Biol Chem 288(41):29573\u201329585","journal-title":"J Biol Chem"},{"issue":"11","key":"5390_CR16","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J et al (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26(11):2326\u20132335","journal-title":"Leukemia"},{"issue":"2","key":"5390_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/bjh.12622","volume":"164","author":"AK Gandhi","year":"2014","unstructured":"Gandhi AK, Mendy D, Waldman M, Chen G, Rychak E, Miller K et al (2014) Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol 164(2):233\u2013244","journal-title":"Br J Haematol"},{"issue":"18","key":"5390_CR18","doi-asserted-by":"publisher","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","volume":"118","author":"YX Zhu","year":"2011","unstructured":"Zhu YX, Braggio E, Shi CX, Bruins LA, Schmidt JE, Van Wier S et al (2011) Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 118(18):4771\u20134779","journal-title":"Blood"},{"issue":"3","key":"5390_CR19","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.3892\/ol.2017.6502","volume":"14","author":"Y Jian","year":"2017","unstructured":"Jian Y, Gao W, Geng C, Zhou H, Leng Y, Li Y et al (2017) Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. Oncol Lett 14(3):3243\u20133248","journal-title":"Oncol Lett"},{"issue":"12","key":"5390_CR20","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2018-01-821769","volume":"132","author":"QL Sievers","year":"2018","unstructured":"Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132(12):1293\u20131303","journal-title":"Blood"},{"issue":"1","key":"5390_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41375-018-0205-y","volume":"33","author":"J Liu","year":"2019","unstructured":"Liu J, Song T, Zhou W, Xing L, Wang S, Ho M et al (2019) A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia 33(1):171\u2013180","journal-title":"Leukemia"},{"issue":"1562","key":"5390_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.605989","volume":"8","author":"L Zhou","year":"2020","unstructured":"Zhou L, Yu W, Jayabalan DS, Niesvizky R, Jaffrey SR, Huang X et al (2020) Caspase-8 inhibition prevents the cleavage and degradation of E3 ligase substrate receptor cereblon and potentiates its biological function. Front Cell Dev Biol 8(1562):605989","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"5390_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1124\/jpet.121.000818","volume":"379","author":"L Zhou","year":"2021","unstructured":"Zhou L, Huang X, Niesvizky R, Pu Z, Xu G (2021) Caspase-8 regulates the antimyeloma activity of bortezomib and lenalidomide. J Pharmacol Exp Ther 379(3):303\u2013309","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"5390_CR24","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1021\/acs.jproteome.9b00208","volume":"18","author":"Q Duan","year":"2019","unstructured":"Duan Q, Li D, Xiong L, Chang Z, Xu G (2019) SILAC quantitative proteomics and biochemical analyses reveal a novel molecular mechanism by which ADAM12S promotes the proliferation, migration, and invasion of small cell lung cancer cells through upregulating hexokinase 1. J Proteome Res 18(7):2903\u20132914","journal-title":"J Proteome Res"},{"issue":"3","key":"5390_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41388-020-01551-1","volume":"40","author":"Z Hu","year":"2021","unstructured":"Hu Z, Wang X, Li D, Cao L, Cui H, Xu G (2021) UFBP1, a key component in ufmylation, enhances drug sensitivity by promoting proteasomal degradation of oxidative stress-response transcription factor Nrf2. Oncogene 40(3):647\u2013662","journal-title":"Oncogene"},{"issue":"4","key":"5390_CR26","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/aps.2017.163","volume":"39","author":"D Chen","year":"2018","unstructured":"Chen D, Li Y-P, Yu Y-X, Zhou T, Liu C, Fei E-K et al (2018) Dendritic cell nuclear protein-1 regulates melatonin biosynthesis by binding to BMAL1 and inhibiting the transcription of N-acetyltransferase in C6 cells. Acta Pharmacol Sin 39(4):597\u2013606","journal-title":"Acta Pharmacol Sin"},{"issue":"2480","key":"5390_CR27","volume":"11","author":"G Liu","year":"2020","unstructured":"Liu G, Liu Q, Yan B, Zhu Z, Xu Y (2020) USP7 inhibition alleviates H2O2-induced injury in chondrocytes via inhibiting NOX4\/NLRP3 pathway. Front Pharmacol 11(2480):617270","journal-title":"Front Pharmacol"},{"issue":"9","key":"5390_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/aps.2015.36","volume":"36","author":"Q-Q Zhang","year":"2015","unstructured":"Zhang Q-Q, Wang W-j, Li J, Yang N, Chen G, Wang Z et al (2015) Cathepsin L suppression increases the radiosensitivity of human glioma U251 cells via G2\/M cell cycle arrest and DNA damage. Acta Pharmacol Sin 36(9):1113\u20131125","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"5390_CR29","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/s41401-019-0249-1","volume":"40","author":"XH Chen","year":"2019","unstructured":"Chen XH, Xu YJ, Wang XG, Lin P, Cao BY, Zeng YY et al (2019) Mebendazole elicits potent antimyeloma activity by inhibiting the USP5\/c-Maf axis. Acta Pharmacol Sin 40(12):1568\u20131577","journal-title":"Acta Pharmacol Sin"},{"issue":"11","key":"5390_CR30","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/aps.2015.54","volume":"36","author":"X Hou","year":"2015","unstructured":"Hou X, Si J, Ren H, Chen D, Wang H, Ying Z et al (2015) Parkin represses 6-hydroxydopamine-induced apoptosis via stabilizing scaffold protein p62 in PC12 cells. Acta Pharmacol Sin 36(11):1300\u20131307","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"5390_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.4062\/biomolther.2020.089","volume":"29","author":"W Yu","year":"2021","unstructured":"Yu W, Wang B, Zhou L, Xu G (2021) Endoplasmic reticulum stress-mediated p62 downregulation inhibits apoptosis via c-Jun upregulation. Biomol Ther (Seoul) 29(2):195\u2013204","journal-title":"Biomol Ther (Seoul)"},{"issue":"9","key":"5390_CR32","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1021\/acs.jproteome.1c00437","volume":"20","author":"J Lu","year":"2021","unstructured":"Lu J, Jiang H, Li D, Chen T, Wang Y, Pu Z et al (2021) Proximity labeling, quantitative proteomics, and biochemical studies revealed the molecular mechanism for the inhibitory effect of indisulam on the proliferation of gastric cancer cells. J Proteome Res 20(9):4462\u20134474","journal-title":"J Proteome Res"},{"issue":"1","key":"5390_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41401-018-0064-0","volume":"40","author":"DK Guo","year":"2019","unstructured":"Guo DK, Zhu Y, Sun HY, Xu XY, Zhang S, Hao ZB et al (2019) Pharmacological activation of REV-ERB\u03b1 represses LPS-induced microglial activation through the NF-\u00b5B pathway. Acta Pharmacol Sin 40(1):26\u201334","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"5390_CR34","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1021\/acs.jproteome.3c00107","volume":"22","author":"X Wang","year":"2023","unstructured":"Wang X, Cao L, Jiang H, Zhou L, Hu Z, Xu G (2023) Proximity proteomics and biochemical analysis reveal a noncanonical function for UFM1-specific protease 1 in the p62 body formation. J Proteome Res 22(7):2352\u20132363","journal-title":"J Proteome Res"},{"issue":"1","key":"5390_CR35","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1038\/s41598-020-61027-w","volume":"10","author":"S Tateno","year":"2020","unstructured":"Tateno S, Iida M, Fujii S, Suwa T, Katayama M, Tokuyama H et al (2020) Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide. Sci Rep 10(1):4012","journal-title":"Sci Rep"},{"issue":"31","key":"5390_CR36","doi-asserted-by":"publisher","first-page":"16197","DOI":"10.1074\/jbc.M116.731927","volume":"291","author":"HM Ng","year":"2016","unstructured":"Ng HM, Wei L, Lan L, Huen MS (2016) The Lys63-deubiquitylating enzyme BRCC36 Limits DNA break processing and repair. J Biol Chem 291(31):16197\u201316207","journal-title":"J Biol Chem"},{"issue":"11","key":"5390_CR37","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3390\/biom10111503","volume":"10","author":"J Rabl","year":"2020","unstructured":"Rabl J (2020) BRCA1-A and BRISC: multifunctional molecular machines for ubiquitin signaling. Biomolecules 10(11):1503","journal-title":"Biomolecules"},{"issue":"1","key":"5390_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.celrep.2013.08.025","volume":"5","author":"H Zheng","year":"2013","unstructured":"Zheng H, Gupta V, Patterson-Fortin J, Bhattacharya S, Katlinski K, Wu J et al (2013) A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses. Cell Rep 5(1):180\u2013193","journal-title":"Cell Rep"},{"issue":"12","key":"5390_CR39","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1096\/fj.15-274050","volume":"29","author":"Y Liu","year":"2015","unstructured":"Liu Y, Huang X, He X, Zhou Y, Jiang X, Chen-Kiang S et al (2015) A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. FASEB J 29(12):4829\u20134839","journal-title":"FASEB J"},{"issue":"10","key":"5390_CR40","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1212\/01.WNL.0000146196.01316.A2","volume":"63","author":"JJ Higgins","year":"2004","unstructured":"Higgins JJ, Pucilowska J, Lombardi RQ, Rooney JP (2004) A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63(10):1927\u20131931","journal-title":"Neurology"},{"issue":"4","key":"5390_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/jmedgenet-2016-104117","volume":"54","author":"A Sheereen","year":"2017","unstructured":"Sheereen A, Alaamery M, Bawazeer S, Al Yafee Y, Massadeh S, Eyaid W (2017) A missense mutation in the CRBN gene that segregates with intellectual disability and self-mutilating behaviour in a consanguineous Saudi family. J Med Genet 54(4):236\u2013240","journal-title":"J Med Genet"},{"issue":"6","key":"5390_CR42","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","volume":"8","author":"RC Kane","year":"2003","unstructured":"Kane RC, Bross PF, Farrell AT, Pazdur R (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 8(6):508\u2013513","journal-title":"Oncologist"},{"issue":"9","key":"5390_CR43","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3109\/10428194.2013.847935","volume":"55","author":"Y Zou","year":"2014","unstructured":"Zou Y, Lin M, Sheng Z, Niu S (2014) Bortezomib and lenalidomide as front-line therapy for multiple myeloma. Leuk Lymphoma 55(9):2024\u20132031","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"5390_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13046-021-02012-7","volume":"40","author":"J Yang","year":"2021","unstructured":"Yang J, Zhou Y, Xie S, Wang J, Li Z, Chen L et al (2021) Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res 40(1):206","journal-title":"J Exp Clin Cancer Res"},{"issue":"7760","key":"5390_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41586-019-1232-1","volume":"570","author":"M Walden","year":"2019","unstructured":"Walden M, Tian L, Ross RL, Sykora UM, Byrne DP, Hesketh EL et al (2019) Metabolic control of BRISC\u2013SHMT2 assembly regulates immune signalling. Nature 570(7760):194\u2013199","journal-title":"Nature"},{"issue":"26","key":"5390_CR46","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1074\/jbc.RA118.002246","volume":"293","author":"J Yang","year":"2018","unstructured":"Yang J, Huang M, Zhou L, He X, Jiang X, Zhang Y et al (2018) Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun. J Biol Chem 293(26):10141\u201310157","journal-title":"J Biol Chem"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05390-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05390-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05390-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:22:47Z","timestamp":1723555367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05390-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["5390"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05390-1","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"17 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest with the contents of this article<i>.<\/i>","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve research of human subject, and did not require the ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"No consent to publish had to be obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"349"}}